Adult Clinical Trials

Gastrointestinal Cancers - Colorectal cancers and cancers of the stomach, esophagus and other digestive organs

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact the Gastrointestinal (GI) Clinical Trials Office at 919-668-1861.

17 trials identified.

A Phase I Trial of the IGF-1R Antibody AMG 479 in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer (The RAP Trial)
Phase: Phase I
Sponsor: PI initiated
Principal Investigator: Jeffrey Clarke
Contact: Anthony Amara
Phone: 919.668.1861
Reference Number: 00021317
View this trial at ClinicalTrials.gov

A Multicenter Randomized Phase II Study of NPC-1C in Combination with Gemcitabine and nab-Paclitaxel versus Gemcitabine and nab-Paclitaxel alone in Patients with Metastatic or Locally Advanced Pancreatic Cancer Previously Treated with FOLFIRINOX
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Michael Morse
Contact: GI Oncology Clinical Trials Office
Phone: 919.668.1861
Reference Number: 00043261
View this trial at ClinicalTrials.gov

A Pilot Study of Active Immunotherapy with CEA(6D) VRP Vaccine (AVX701) in Patients with Stage III Colorectal Cancer
Phase: Phase II
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Michael Morse
Contact: Ireka Burrus
Phone: 919.668.1861
Reference Number: 00045976
View this trial at ClinicalTrials.gov

Cabozantinib (XL184) with Panitumumab in Subjects with RAS Wild-Type Metastatic Colorectal Cancer and Cabozantinib Monotherapy in Subjects with MET Amplified Treatment-Refractory Colorectal Cancer
Phase: Phase I
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: John Strickler
Contact: GI Oncology Clinical Trials Office
Phone: 919.668.1861
Reference Number: 00049983
View this trial at ClinicalTrials.gov

DEK-DKK1-P102: A Four Part, Phase 1, Multi-center, Open- label Study of DKN-01 in Combination with Weekly Paclitaxel; Part A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Part B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro- esophageal Junction Tumors; Part C: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal or Gastro-esophageal Junction Adenocarcinoma; Part D: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Squamous Cell Cancer; Part E: An Expansion Cohort in Patients with Relapsed or Refractory Gastric Adenocarcinoma with Wnt Signaling Alterations
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: John Strickler
Contact: GI Oncology Clinical Trials Office
Phone: 919.668.1861
Reference Number: 00049984
View this trial at ClinicalTrials.gov

A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations, in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and non-MSI-H Colon Cancer
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Michael Morse
Contact: GI Oncology Clinical Trials Office
Phone: 919.668.1861
Reference Number: 00052582
View this trial at ClinicalTrials.gov

A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients with Relapsed/Refractory Metastatic Colorectal Carcinoma
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: John Strickler
Contact: GI Oncology Clinical Trials Office
Phone: 919.668.1861
Reference Number: 00056149

Phase 2 Study of ADXS11-001 in Subjects With Persistent/Recurrent, Loco-Regional or Metastatic Squamous Cell Carcinoma of the Anorectal Canal
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Hope Uronis
Contact: GI Oncology Clinical Trials Office
Phone: 919.668.1861
Reference Number: 00064449
View this trial at ClinicalTrials.gov

Duke Gastrointestinal Biomarkers and Epidemiology Study
Phase: N/A
Sponsor: Internal Investigator Initiated Non-therapeutic/Non-interventional
Principal Investigator: Qingyi Wei
Contact: Epidemiology Oncology Research Team
Phone: 919.668.7383
Reference Number: 00065084

A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Michael Morse
Contact: GI Oncology Clinical Research Trials Office
Phone: 919.668.1861
Reference Number: 00066636
View this trial at ClinicalTrials.gov

A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination with Pembrolizumab in Patients with Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Hope Uronis
Contact: GI Oncology Clinical Trials Office
Phone: 919.668.1861
Reference Number: 00068590
View this trial at ClinicalTrials.gov

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS 5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: John Strickler
Contact: GI Oncology Clinical Trials Office
Phone: 919.668.1861
Reference Number: 00069751
View this trial at ClinicalTrials.gov

ECOG-ACRIN EA2142: Randomized Phase II Study of Platinum and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
Phase: Phase II
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: GI Oncology Clinical Research Trials Office
Phone: 919.668.1861
Reference Number: 00069873
View this trial at ClinicalTrials.gov

A Phase III Study of Pembrolizumab vs. Chemotherapy in Microsatellite Instability- High or Mismatch Repair Deficient Stage IV Colorectal Cancer
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Michael Morse
Contact: GI Oncology Clinical Research Trials Office
Phone: 919.668.1861
Reference Number: 00070459
View this trial at ClinicalTrials.gov

Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 in Advanced Solid Tumors and in Combination with FOLFIRI for Patients with Previously Treated Metastatic Colorectal or Gastric Cancer
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: John Strickler
Contact: GI Oncology Clinical Research Trials Office
Phone: 919.668.1861
Reference Number: 00072844
View this trial at ClinicalTrials.gov

A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Hope Uronis
Contact: GI Oncology Clinical Research Trials Office
Phone: 919.668.1861
Reference Number: 00072847
View this trial at ClinicalTrials.gov

Alliance A021501: Preoperative Extended Chemotherapy versus Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Phase: Phase II
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: GI Oncology Clinical Research Trials Office
Phone: 919.668.1861
Reference Number: 00078527